At a glance
- Originator Unknown
- Developer Nonindustrial source
- Class Antineoplastics
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 08 Feb 2001 Profile reviewed but no significant changes made
- 22 Oct 1997 No-Development-Reported for Cancer in Croatia (Unknown route)
- 22 Oct 1997 No-Development-Reported for Cancer in Italy (Unknown route)